Seribantumab
Information
- Drug Name
- Seribantumab
- Description
- Entry(CIViC)
- 1
CIViC
| Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| ovarian cancer | NRG1 EXPRESSION NRG1 EXPRESSION | D |
Predictive
|
Supports
|
Sensitivity/Response |
N/A
|
3 | 20227043 | Detail |
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| An NRG1-ERBB3 autocrine signal-transducing loop wa... | NRG1 | NRG1 EXPRESSION NRG1 EXPRESSION | Sensitivity | true | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04383210 | Active, not recruiting | Phase 2 | Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors | September 29, 2020 | March 2025 |
| NCT04790695 | Completed | Phase 2 | Single Patient Protocol for an NRG1 Fusion Positive Metastatic Pancreatic Cancer Patient Using Seribantumab | March 29, 2021 | December 22, 2021 |
| NCT03241810 | Terminated | Phase 2 | Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer | August 15, 2017 | November 30, 2018 |